Nursing CME Courses
Nursing CME Courses
This activity is intended for pediatric oncology nurses, pediatric nurses, oncology nurses, nurse practitioners, nurse managers, infusion nurses, research nurses, physician assistants, and other health care providers who care for or have an interest in pediatric patients with high-risk neuroblastoma
Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.
By the end of the session the participant will be able to:
- Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
- Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
- Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
- Describe the challenges and barriers to care associated with treating patients with mCRC
At the conclusion of this activity, participants will be able to:
- Discuss the problem of “financial harm” for individual patients
- List the three steps of the “First, Do No Financial Harm” framework
- Demonstrate strategies for discussing costs and the value of recommended medical procedures with price-sensitive patients
Includes Topics in
- HR deficiencies and BRCA mutations
- Recurrent ovarian cancer
- Data on available and emerging PARP inhibitors
- Personalizing treatment selection
- Companion Diagnostics
Some have suggested that criteria used for the past two decades are inadequate for addressing the disease burden of RA because by the time a physician detects rheumatoid nodules or radiographic erosion, the optimal time has passed for treatment initiation, representing a gap in care relating to diagnosis of disease. Another potential gap is illustrated by studies in which researchers demonstrated that a systematic, objective approach to therapy with Disease Activity Score-driven therapy yields superior outcomes to routine care.
By the end of the session the participant will be able to:
- Describe the pathophysiology of RA such that it might inform treatment mechanisms.
- Describe professional guideline recommendations’ approaches to the diagnosis and treatment of RA and, where applicable, apply them to patient cases
- Identify the currently available and emerging pharmacotherapeutic treatments for management of RA and apply them to patient cases using evidence-based medicine.
- Evaluate a treatment plan for a specific patient with RA to optimize safety and efficacy, suggesting modifications for improvement, including the management of comorbidities.
- Describe the challenges and barriers to care associated with treating patients with RA.